{"id":"W2915181639","doi":"10.1093/eurheartj/ehw069","title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2","year":2016,"lang":"en","type":"review","venue":"European Heart Journal","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Cilag; Janssen Pharmaceuticals; St. Jude Medical; AstraZeneca; Allergan; National Institutes of Health; H. Lundbeck A/S; Servier; Astellas Pharma; Daiichi-Sankyo; Bundesministerium für Bildung und Forschung; Fondation Leducq; British Heart Foundation; European Society of Cardiology; Boston Scientific Corporation; Bayer Vital; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; Alere; Bayer HealthCare; European Commission; Sanofi; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Pfizer","keywords":"Medicine; Atrial fibrillation; Stroke (engine); Thrombolysis; Internal medicine; Oral anticoagulant; Intensive care medicine; Anticoagulant; Clinical trial; Vitamin k; Cardiology; Warfarin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001344903,0.0003286758,0.001187786,0.0003321881,0.0001679816,0.0001725383,0.00007113783,0.00008861999,0.00005076297],"category_scores_gemma":[0.0001803003,0.000206301,0.0005933046,0.0001629014,0.0000417269,0.0002257632,0.00007758188,0.0002553887,0.00002970253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007304864,"about_ca_system_score_gemma":0.0001448459,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":4.721236e-7,"about_ca_topic_score_gemma":5.464522e-7,"domain_scores_codex":[0.9975628,0.0004654663,0.0008428265,0.0003280049,0.0004562377,0.0003447058],"domain_scores_gemma":[0.9988568,0.0001411778,0.0005197768,0.0001932111,0.00009530371,0.0001937084],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003859066,0.00001341125,0.1532259,0.001966201,0.0006772952,0.00006483826,0.00005943342,0.00001087524,5.666608e-7,0.00001262943,0.00104983,0.8425331],"study_design_scores_gemma":[0.006327143,0.0005982584,0.06931995,0.01146785,0.001489659,0.0001166836,0.000006290479,0.00001236978,2.400934e-7,0.000006725612,0.9104019,0.000252985],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02603119,0.9671552,0.0007679126,0.000390754,0.001055814,0.004313053,0.00006695932,0.00004744309,0.0001717304],"genre_scores_gemma":[0.00240178,0.9844173,0.002652674,0.00004574276,0.009149224,0.000002711241,0.0002503636,0.0001521955,0.000928064],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.909352,"threshold_uncertainty_score":0.8412711,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1581573846459282,"score_gpt":0.3960271141982049,"score_spread":0.2378697295522767,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}